U.S. markets closed
  • S&P Futures

    4,150.00
    +3.75 (+0.09%)
     
  • Dow Futures

    34,224.00
    +41.00 (+0.12%)
     
  • Nasdaq Futures

    13,350.00
    +4.00 (+0.03%)
     
  • Russell 2000 Futures

    2,207.40
    +4.10 (+0.19%)
     
  • Crude Oil

    65.60
    +0.32 (+0.49%)
     
  • Gold

    1,837.40
    +1.30 (+0.07%)
     
  • Silver

    27.72
    +0.05 (+0.17%)
     
  • EUR/USD

    1.2148
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • Vix

    21.84
    +2.18 (+11.09%)
     
  • GBP/USD

    1.4137
    -0.0007 (-0.05%)
     
  • USD/JPY

    108.7400
    +0.1200 (+0.11%)
     
  • BTC-USD

    56,987.71
    +1,470.68 (+2.65%)
     
  • CMC Crypto 200

    1,531.97
    +1,289.30 (+531.28%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    0.00 (0.00%)
     

Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Kiniksa Pharmaceuticals, Ltd.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11th, 2020 at 1:10 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical-stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways that are implicated across a spectrum of diseases. For more information, please visit www.kiniksa.com.

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com